Finding the right dose for cancer therapeutics--can we do better?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20145182.
- Also identified by DOI 10.1158/1078-0432.CCR-09-3246.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few patients. In this issue of Clinical Cancer Research, Jain and colleagues provide evidence that lower doses may be as effective as maximum-tolerated doses in the treatment of cancer patients.
Medical subject headings
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Neoplasms